KW-0761 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
26HTLV-1-associated myelopathy4

26. HTLV-1-associated myelopathy


Clinical trials : 28 Drugs : 48 - (DrugBank : 28) / Drug target genes : 38 - Drug target pathways : 127
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JMA-IIA00324
29/06/201723/01/2018A Phase 3 Study of KW-0761 (Mogamulizumab) in Subjects with HTLV-1 Associated Myelopathy (HAM)A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM) HTLV-1 associated Myelopathy (HAM)Intervention type:DRUG. Intervention1:KW-0761, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP. Control intervention1:Placebo, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP.Kyowa Kirin Co., LtdNULLCompleted>=20 YEARSNo LimitBOTH52Phase 3Japan
2JPRN-JapicCTI-173608
01/6/201706/06/2017A Phase 3 Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM)A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM) HTLV-1 associated Myelopathy (HAM)Intervention name : KW-0761
INN of the intervention : Mogamulizumab
Dosage And administration of the intervention : 0.3 mg/kg, IV
Kyowa Hakko Kirin Co., Ltd.NULLcomplete20BOTH52Phase 3NULL
3NCT03191526
(ClinicalTrials.gov)
May 22, 201713/6/2017A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM)HTLV-1 Associated MyelopathyDrug: KW-0761 0.3 mg/kg IV;Drug: Placebo (saline)Kyowa Kirin Co., Ltd.NULLCompleted20 YearsN/AAll66Phase 3Japan
4JPRN-UMIN000016683
2015/03/1305/03/2015Novel autologous dendritic cell vaccine therapy targeting HTLV-1 specific antigen Combined with anti-CCR4 antibody for previously treated patients with adult T-cell leukemia. A phase Ia/Ib study. Adult T-cell leukemia/lymphomaTax-targeting DC vaccine
KW-0761 (Mogamulizumab)
Japan Agency for Medical Research and DevelopmentNational Hospital Organization Kyushu Cancer CenterComplete: follow-up continuing20years-old75years-oldMale and Female9Phase 1Japan